Akero therapeutics chief development officer Yale sells $89k in stock

Akero Therapeutics (NASDAQ:AKRO) Chief Development Officer Yale Catriona sold 1,633 shares of common stock on June 18, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The $4.35 billion market cap company has seen its stock surge over 130% in the past year, currently trading near its 52-week high of $58.40.

The shares were sold at a weighted-average price of $54.84, for a total transaction value of $89,553. The prices for the transactions ranged from $54.33 to $54.84. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $60 to $109.

Following the transaction, Yale directly owns 90,598 shares of Akero Therapeutics.

The sale was to cover tax withholding obligations related to the vesting of restricted stock units, according to a footnote in the filing.

In other recent news, Akero Therapeutics has been in the spotlight due to its promising developments in liver fibrosis treatment. The company recently presented positive results from its Phase 2b SYMMETRY trial, published in the New England Journal of Medicine, indicating that its drug efruxifermin (EFX) may improve liver fibrosis in patients with cirrhosis caused by metabolic dysfunction-associated steatohepatitis (MASH). The trial showed significant improvements in fibrosis among participants, with EFX demonstrating a favorable safety profile. Analysts have taken note, with Jefferies maintaining a Buy rating and a price target of $75, citing the robust data as potentially positioning Akero as an acquisition target. Citi and Morgan Stanley (NYSE:MS) have also maintained Buy and Overweight ratings, though they have adjusted their price targets to $78 and $84, respectively, reflecting updated market conditions and financial models.

Clear Street has initiated coverage on Akero with a Buy rating and a price target of $49, highlighting the "best-in-class potential" of EFX for treating various stages of non-alcoholic steatohepatitis (NASH). Akero’s financial standing remains strong, with $1.1 billion in cash reserves, expected to support operations into 2028. The ongoing Phase 3 SYNCHRONY program, consisting of three global clinical trials, is closely watched by investors as Akero advances its clinical efforts. Despite some adjustments in price targets, the promising trial results and strategic positioning of EFX continue to attract positive attention from analysts.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.